{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T22:12:32Z","timestamp":1794262352144,"version":"4.9.0"},"reference-count":40,"publisher":"American Society of Hematology","issue":"15","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,8,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Tumor-associated macrophages (TAMs) within the tumor microenvironment (TME) play an important role in tumor growth and progression. TAMs have been involved in producing immunosuppressive TME via various factors; however, the underlying mechanisms remain unclear in B-cell lymphoma, including mantle cell lymphoma (MCL). We identified that chemokine receptor-1 (CCR1) is highly expressed on monocytes (Mo) and macrophages (M\u03a6), and CCR1 pharmacological inhibition or CCR1 siRNA abolished lymphoma-mediated Mo\/M\u03a6 migration in a chemotaxis assay. The deficiency of host CCR1 (CCR1 KO) was associated with decreased infiltration of peritoneal-M\u03a6 compared with WT-CCR1. Functional studies indicated that the genetic depletion of CCR1 or treatment inhibited protumor M\u03a6 (M2-like) phenotype by decreasing CD206 and IL-10 expression. Moreover, CCR1 depletion reprogrammed M\u03a6 toward an MHCII+\/TNF\u03b1+ immunogenic phenotype. Mechanistically, protumor M\u03a6 driven\u2013IL-10 provides a positive feedback loop to tumor-CCL3 by regulating the CCL3 promoter via STAT1 signaling. Therapeutic in vivo targeting of CCR1 with CCR1 antagonist BX-471 significantly reduced FC-muMCL1 mouse tumors in the syngeneic MCL model by the depletion of M2-TAMs and increased infiltration of cytotoxic CD8+ T cells. Our study established that CCR1 exerts a pivotal role in macrophage programming, thus shaping protumor TME and lymphoma progression. CCR1 inhibition through CCR1 antagonists may be a promising therapeutic strategy to reprogram macrophages in lymphoma-TME and achieve better clinical outcomes in patients.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022008722","type":"journal-article","created":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T14:20:02Z","timestamp":1673446802000},"page":"3952-3967","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":42,"title":["Blockade of CCR1 induces a phenotypic shift in macrophages and triggers a favorable antilymphoma activity"],"prefix":"10.1182","volume":"7","author":[{"given":"Kang","family":"Le","sequence":"first","affiliation":[{"name":"1Department of Biochemistry and Molecular Medicine, George Washington University, George Washington University's Cancer Center (GWCC), Washington DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Sun","sequence":"additional","affiliation":[{"name":"1Department of Biochemistry and Molecular Medicine, George Washington University, George Washington University's Cancer Center (GWCC), Washington DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javid","family":"Ghaemmaghami","sequence":"additional","affiliation":[{"name":"1Department of Biochemistry and Molecular Medicine, George Washington University, George Washington University's Cancer Center (GWCC), Washington DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell R.","family":"Smith","sequence":"additional","affiliation":[{"name":"2Department of Medicine, School of Medicine and Health Sciences, George Washington University, GWCC, Washington DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. K. Eddie","family":"Ip","sequence":"additional","affiliation":[{"name":"3Department of Immunology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2143-9672","authenticated-orcid":false,"given":"Tycel","family":"Phillips","sequence":"additional","affiliation":[{"name":"4Department of Hematology, University of Michigan, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2081-3941","authenticated-orcid":false,"given":"Mamta","family":"Gupta","sequence":"additional","affiliation":[{"name":"1Department of Biochemistry and Molecular Medicine, George Washington University, George Washington University's Cancer Center (GWCC), Washington DC"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,7,28]]},"reference":[{"issue":"suppl_4","key":"2023080716445940100_bib1","doi-asserted-by":"crossref","first-page":"iv62","DOI":"10.1093\/annonc\/mdx223","article-title":"Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Dreyling","year":"2017","journal-title":"Ann Oncol"},{"issue":"8","key":"2023080716445940100_bib2","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1080\/10428194.2017.1403602","article-title":"Treatment for patients with relapsed\/refractory mantle cell lymphoma: European-based recommendations","volume":"59","author":"Dreyling","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"2023080716445940100_bib3","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1002\/ajh.24797","article-title":"Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management","volume":"92","author":"Vose","year":"2017","journal-title":"Am J Hematol"},{"issue":"28","key":"2023080716445940100_bib4","doi-asserted-by":"crossref","first-page":"7013","DOI":"10.1200\/JCO.2005.01.1825","article-title":"High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine","volume":"23","author":"Romaguera","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2023080716445940100_bib5","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1182\/blood-2011-09-370320","article-title":"CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte","volume":"121","author":"Delarue","year":"2013","journal-title":"Blood"},{"issue":"13","key":"2023080716445940100_bib6","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1056\/NEJMoa1701769","article-title":"Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma","volume":"377","author":"Le Gouill","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"2023080716445940100_bib7","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/annonc\/mdn656","article-title":"Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study","volume":"20","author":"Goy","year":"2009","journal-title":"Ann Oncol"},{"issue":"5","key":"2023080716445940100_bib8","doi-asserted-by":"crossref","first-page":"e211","DOI":"10.3324\/haematol.2018.205229","article-title":"Ibrutinib for the treatment of relapsed\/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis","volume":"104","author":"Rule","year":"2019","journal-title":"Haematologica"},{"issue":"6","key":"2023080716445940100_bib9","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1002\/ajh.25796","article-title":"Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients","volume":"95","author":"Zhao","year":"2020","journal-title":"Am J Hematol"},{"issue":"11","key":"2023080716445940100_bib10","doi-asserted-by":"crossref","first-page":"108870","DOI":"10.1016\/j.celrep.2021.108870","article-title":"Transcriptional programming drives Ibrutinib-resistance evolution in mantle cell lymphoma","volume":"34","author":"Zhao","year":"2021","journal-title":"Cell Rep"},{"issue":"24","key":"2023080716445940100_bib11","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.1182\/blood-2016-06-720490","article-title":"Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphoma","volume":"128","author":"Chiron","year":"2016","journal-title":"Blood"},{"issue":"1","key":"2023080716445940100_bib12","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1158\/1078-0432.CCR-15-0987","article-title":"ROS-Induced CXCR4 signaling regulates mantle cell lymphoma (MCL) cell survival and drug resistance in the bone marrow microenvironment via autophagy","volume":"22","author":"Chen","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2023080716445940100_bib13","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.immuni.2014.06.010","article-title":"Tumor-associated macrophages: from mechanisms to therapy","volume":"41","author":"Noy","year":"2014","journal-title":"Immunity"},{"issue":"1","key":"2023080716445940100_bib14","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.cell.2010.03.014","article-title":"Macrophage diversity enhances tumor progression and metastasis","volume":"141","author":"Qian","year":"2010","journal-title":"Cell"},{"issue":"19-20","key":"2023080716445940100_bib15","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1101\/gad.314617.118","article-title":"Roles of the immune system in cancer: from tumor initiation to metastatic progression","volume":"32","author":"Gonzalez","year":"2018","journal-title":"Genes Dev"},{"issue":"1","key":"2023080716445940100_bib16","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12929-019-0568-z","article-title":"Tumor-associated macrophages: an accomplice in solid tumor progression","volume":"26","author":"Chen","year":"2019","journal-title":"J\u00a0Biomed Sci"},{"issue":"24","key":"2023080716445940100_bib17","doi-asserted-by":"crossref","first-page":"7254","DOI":"10.1158\/0008-5472.CAN-13-0750","article-title":"Lenalidomide inhibits lymphangiogenesis in preclinical models of mantle cell lymphoma","volume":"73","author":"Song","year":"2013","journal-title":"Cancer Res"},{"issue":"1","key":"2023080716445940100_bib18","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3109\/10428194.2014.901511","article-title":"Involvement of tumor-associated macrophage activation in\u00a0vitro during development of a novel mantle cell lymphoma cell line, PF-1, derived from a typical patient with relapsed disease","volume":"56","author":"Pham","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"14","key":"2023080716445940100_bib19","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1182\/bloodadvances.2020003871","article-title":"Mantle cell lymphoma polarizes tumor-associated macrophages into M2-like macrophages, which in turn promote tumorigenesis","volume":"5","author":"Le","year":"2021","journal-title":"Blood Adv"},{"issue":"5","key":"2023080716445940100_bib20","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/nri2972","article-title":"Overcoming hurdles in developing successful drugs targeting chemokine receptors","volume":"11","author":"Schall","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"2023080716445940100_bib21","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1146\/annurev-immunol-032713-120145","article-title":"Chemokines and chemokine receptors: positioning cells for host defense and immunity","volume":"32","author":"Griffith","year":"2014","journal-title":"Annu Rev Immunol"},{"issue":"6","key":"2023080716445940100_bib22","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMra052723","article-title":"The many roles of chemokines and chemokine receptors in inflammation","volume":"354","author":"Charo","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"2023080716445940100_bib23","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1196\/annals.1361.109","article-title":"Chemokine receptors: attractive targets for drug discovery","volume":"1051","author":"Godessart","year":"2005","journal-title":"Ann N Y Acad Sci"},{"issue":"9","key":"2023080716445940100_bib24","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.1182\/blood-2002-08-2383","article-title":"Macrophage inflammatory protein 1-alpha (MIP-1 alpha ) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells","volume":"101","author":"Lentzsch","year":"2003","journal-title":"Blood"},{"issue":"2","key":"2023080716445940100_bib25","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s00277-018-3522-3","article-title":"Prognostic significance of monocyte chemoattractant protein-1 and CC chemokine receptor 2 in diffuse large B cell lymphoma","volume":"98","author":"Li","year":"2019","journal-title":"Ann Hematol"},{"issue":"12","key":"2023080716445940100_bib26","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1359\/jbmr.040910","article-title":"CCR1 chemokines promote the chemotactic recruitment, RANKL development, and motility of osteoclasts and are induced by inflammatory cytokines in osteoblasts","volume":"19","author":"Yu","year":"2004","journal-title":"J\u00a0Bone Miner Res"},{"issue":"1","key":"2023080716445940100_bib27","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1359\/JBMR.051001","article-title":"CCR1 acts downstream of NFAT2 in osteoclastogenesis and enhances cell migration","volume":"21","author":"Ishida","year":"2006","journal-title":"J\u00a0Bone Miner Res"},{"issue":"7","key":"2023080716445940100_bib28","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1038\/leu.2012.370","article-title":"Murine mantle cell lymphoma model cell line","volume":"27","author":"Smith","year":"2013","journal-title":"Leukemia"},{"issue":"14","key":"2023080716445940100_bib29","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1182\/blood-2009-05-220111","article-title":"Monocytes promote tumor cell survival in T-cell lymphoproliferative disorders and are impaired in their ability to differentiate into mature dendritic cells","volume":"114","author":"Wilcox","year":"2009","journal-title":"Blood"},{"issue":"3","key":"2023080716445940100_bib30","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41408-021-00447-x","article-title":"JAK2 activation promotes tumorigenesis in ALK-negative anaplastic large cell lymphoma via regulating oncogenic STAT1-PVT1 lncRNA axis","volume":"11","author":"Le","year":"2021","journal-title":"Blood Cancer J"},{"key":"2023080716445940100_bib31","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.3389\/fonc.2020.01226","article-title":"Deregulation of polycomb repressive complex-2 in mantle cell lymphoma confers growth advantage by epigenetic suppression of cdkn2b","volume":"10","author":"Demosthenous","year":"2020","journal-title":"Front Oncol"},{"issue":"4","key":"2023080716445940100_bib32","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/ng1532","article-title":"Reverse engineering of regulatory networks in human B cells","volume":"37","author":"Basso","year":"2005","journal-title":"Nat Genet"},{"issue":"12","key":"2023080716445940100_bib33","doi-asserted-by":"crossref","first-page":"E223","DOI":"10.1002\/ajh.23838","article-title":"Elevated soluble IL-2Ralpha, IL-8, and MIP-1beta levels are associated with inferior outcome and are independent of MIPI score in patients with mantle cell lymphoma","volume":"89","author":"Sonbol","year":"2014","journal-title":"Am J Hematol"},{"key":"2023080716445940100_bib34","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1146\/annurev-immunol-031210-101312","article-title":"Regulation and functions of the IL-10 family of cytokines in inflammation and disease","volume":"29","author":"Ouyang","year":"2011","journal-title":"Annu Rev Immunol"},{"issue":"5","key":"2023080716445940100_bib35","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/gene.2015.9","article-title":"Interleukin-10 receptor-1 expression in monocyte-derived antigen-presenting cell populations: dendritic cells partially escape from IL-10's inhibitory mechanisms","volume":"16","author":"von Haehling","year":"2015","journal-title":"Genes Immun"},{"issue":"5","key":"2023080716445940100_bib36","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.3109\/10428194.2014.991731","article-title":"Nurse like cells: chronic lymphocytic leukemia associated macrophages","volume":"56","author":"Boissard","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"2023080716445940100_bib37","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1146\/annurev.immunol.26.021607.090326","article-title":"Monocyte-mediated defense against microbial pathogens","volume":"26","author":"Serbina","year":"2008","journal-title":"Annu Rev Immunol"},{"issue":"5","key":"2023080716445940100_bib38","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/bjh.13659","article-title":"CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma","volume":"171","author":"Takahashi","year":"2015","journal-title":"Br J Haematol"},{"issue":"3","key":"2023080716445940100_bib39","doi-asserted-by":"crossref","first-page":"564","DOI":"10.3324\/haematol.2018.196725","article-title":"CCR5 antagonism by maraviroc inhibits Hodgkin lymphoma microenvironment interactions and xenograft growth","volume":"104","author":"Casagrande","year":"2019","journal-title":"Haematologica"},{"issue":"10","key":"2023080716445940100_bib40","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1038\/s41375-019-0463-3","article-title":"CSF1R and BTK inhibitions as novel strategies to disrupt the dialog between mantle cell lymphoma and macrophages","volume":"33","author":"Papin","year":"2019","journal-title":"Leukemia"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/15\/3952\/2069602\/blooda_adv-2022-008722-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/15\/3952\/2069602\/blooda_adv-2022-008722-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T12:45:30Z","timestamp":1691412330000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/15\/3952\/494095\/Blockade-of-CCR1-induces-a-phenotypic-shift-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,28]]},"references-count":40,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2023,8,8]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022008722","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,28]]}}}